Larimar Therapeutics
Leida Rassouli-Taylor is an experienced professional in the field of protein biochemistry and engineering, currently serving as Associate Director at Larimar Therapeutics Inc. since September 2024. Prior roles include Senior Research Scientist at Immunome, Inc. and Scientist in Protein Sciences at Century Therapeutics, Inc., where responsibilities encompassed protein engineering, project management, and involvement in discovery and preclinical phases of various disease programs. Leida began as a Senior Research Investigator I at Amicus Therapeutics, focusing on protein engineering and project management, and also served as a Research Investigator there. Earlier experience includes a postdoctoral position at Joan & Sanford I. Weill Medical College of Cornell University, working on protein crystallography and engineering under Greg Petsko, and completing a PhD in Biochemistry and Biophysics at Brandeis University, where research focused on protein crystallography and directed evolution.
This person is not in any teams
Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in the Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease.